APD403 Demonstrates Control of Nausea and Vomiting after Highly Emetogenic Chemotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase II study of APD403 in the prevention of chemotherapy-induced nausea and vomiting reported positive results in patients receiving highly emetogenic chemotherapy—either high-dose cisplatin, or cyclophosphamide and an anthracycline for breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login